As reported earlier, RBC Capital analyst Randall Stanicky upgraded Endo to Outperform from Sector Perform and raised his price target to $26 from $8. The analyst cites the company's "best-in-class execution" along with his outlook for a favorable cyclical set-up. Stanicky adds that more certainty around the timing of its its generic pipeline, along with tailwinds in its branded business, should lead to a higher stock price. The analyst believes that risk-reward on Endo is favorable at 8.2-times enterprise value to expected EBITDA valuation, even though "hurdles remain".